Sakigake Status Should Not Be Granted to Novartis Products until It Takes Prevention Measures for Approval Delay: Pharma Bureau Chief

Mitsuaki Kamata, Director General, Pharmaceutical Safety and Environmental Health Bureau, MHLW Mitsuaki Kamata, director general of the Pharmaceutical Safety and Environmental Health Bureau, urged Novartis Pharma to seriously reflect on its flaws in the review process for sakigake -designated Zolgensma...read more